AR048360A1 - Formas cristalinas de 5,11-dihidro-11-etil-5-metil-8-(2-((1-oxido-4-quinolinil)oxi)etil)-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-ona y un metodo para su fabricacion. - Google Patents
Formas cristalinas de 5,11-dihidro-11-etil-5-metil-8-(2-((1-oxido-4-quinolinil)oxi)etil)-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-ona y un metodo para su fabricacion.Info
- Publication number
- AR048360A1 AR048360A1 ARP050101292A ARP050101292A AR048360A1 AR 048360 A1 AR048360 A1 AR 048360A1 AR P050101292 A ARP050101292 A AR P050101292A AR P050101292 A ARP050101292 A AR P050101292A AR 048360 A1 AR048360 A1 AR 048360A1
- Authority
- AR
- Argentina
- Prior art keywords
- ethyl
- diazepin
- oxido
- etil
- dipyrido
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title 1
- RNRXQIGKEMFMAZ-UHFFFAOYSA-N 11-ethyl-5-methyl-8-[2-(1-oxidoquinolin-1-ium-4-yl)oxyethyl]dipyrido[2,3-d:2',3'-h][1,4]diazepin-6-one;dihydrate Chemical compound O.O.CN1C(=O)C2=CC(CCOC=3C4=CC=CC=C4[N+]([O-])=CC=3)=CN=C2N(CC)C2=NC=CC=C21 RNRXQIGKEMFMAZ-UHFFFAOYSA-N 0.000 abstract 3
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- 239000000243 solution Substances 0.000 abstract 3
- 230000005855 radiation Effects 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- -1 1-oxido-4-quinolinyl Chemical group 0.000 abstract 1
- BEMBRAMZGVDPMH-UHFFFAOYSA-N 11-ethyl-5-methyl-8-[2-(1-oxidoquinolin-1-ium-4-yl)oxyethyl]dipyrido[2,3-d:2',3'-h][1,4]diazepin-6-one Chemical compound CN1C(=O)C2=CC(CCOC=3C4=CC=CC=C4[N+]([O-])=CC=3)=CN=C2N(CC)C2=NC=CC=C21 BEMBRAMZGVDPMH-UHFFFAOYSA-N 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- CVLAEJNQNKXNNN-UHFFFAOYSA-N diazepin-4-one Chemical compound O=C1C=CC=NN=C1 CVLAEJNQNKXNNN-UHFFFAOYSA-N 0.000 abstract 1
- 150000004683 dihydrates Chemical class 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012047 saturated solution Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicacion 1: La forma cristalina de 5,11-dihidro-11-etil-5-metil-8-{2-{(1-oxido-4-quinolinil)oxi}etil}-6H-dipirido[3,2-b:2',3'-e][1,4]diazepin-6-ona dihidrato que tiene un modelo de difraccion de polvo por rayos X que comprende un pico a 23.4 grados 2 Theta (+- 0.2 grados 2 Theta), en donde dicho modelo de difraccion de polvo por rayos X se hace usando la radiacion Kalfa del Cu. La Forma III cristalina de la 5,11-dihidro-11-etil-5-metil-8-{2-{(1-oxido-4-quinolinil)oxi}etil}-6H- dipirido[3,2-b:2',3'-e][1,4]diazepin-6-ona anhidra que tiene un modelo de difraccion de polvo por rayos X que comprende un pico a 11.6 grados 2 Theta (+- 0.2 grados 2 Theta), en donde dicho modelo de difraccion por rayos X se hace usando la radiacion Kalfa del Cu. Reivindicacion 15: Un método de fabricar la forma cristalina de 5,11-dihidro-11-etil-5-metil-8-{2-{(1-oxido-4-quinolinil)oxi}etil}-6H-dipirido[3,2-b:2',3'-e][1,4]diazepin-6-ona dihidrato segun las reivindicaciones 1, 2, 3, 4, 5 o 6, comprendiendo dicho método las siguientes etapas: a) Disolver 5,11-dihidro-11-etil-5-metil-8-{2-{(1-oxido-4-quinolinil)oxi}etil}-6H-dipirido[3,2-b:2',3'-e][1,4]diazepin-6-ona en una mezcla de H2O y de un disolvente miscible en agua, para formar una solucion saturada o casi saturada, con la condicion de que la cantidad de H2O debe ser al menos la cantidad requerida para formar un dihidrato estequiométrico; b) enfriar la solucion para precipitar el 5,11-dihidro-11-etil-5-metil-8-{2- {(1-oxido-4-quinolinil)oxi}etil}-6H-dipirido[3,2-b:2',3'-e][1,4]diazepin-6-ona dihidrato fuera de la solucion; c) separar el precipitado de la solucion; y d) secar el solido hasta que todos los disolventes de la superficie han sido eliminados.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55935404P | 2004-04-02 | 2004-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048360A1 true AR048360A1 (es) | 2006-04-19 |
Family
ID=34963561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101292A AR048360A1 (es) | 2004-04-02 | 2005-04-01 | Formas cristalinas de 5,11-dihidro-11-etil-5-metil-8-(2-((1-oxido-4-quinolinil)oxi)etil)-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-ona y un metodo para su fabricacion. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7309700B2 (es) |
| EP (1) | EP1740586A2 (es) |
| JP (1) | JP2007530681A (es) |
| KR (1) | KR20070014164A (es) |
| CN (1) | CN1938306A (es) |
| AR (1) | AR048360A1 (es) |
| AU (1) | AU2005230922A1 (es) |
| BR (1) | BRPI0509586A (es) |
| CA (1) | CA2558817A1 (es) |
| EA (1) | EA200601816A1 (es) |
| EC (1) | ECSP066904A (es) |
| IL (1) | IL178352A0 (es) |
| MX (1) | MXPA06011324A (es) |
| NO (1) | NO20064422L (es) |
| PE (1) | PE20060164A1 (es) |
| TW (1) | TW200602340A (es) |
| UY (1) | UY28827A1 (es) |
| WO (1) | WO2005097796A2 (es) |
| ZA (1) | ZA200605930B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1983997A4 (en) * | 2006-01-31 | 2009-06-17 | Thallion Pharmaceuticals Inc | CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE |
| EP2900240B1 (en) * | 2012-09-26 | 2020-01-08 | Merck Sharp & Dohme Corp. | Crystalline form of a reverse transcriptase inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI270547B (en) | 2000-06-16 | 2007-01-11 | Boehringer Ingelheim Ca Ltd | Non-nucleoside reverse transcriptase inhibitors |
| US6759533B2 (en) | 2002-06-28 | 2004-07-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors |
-
2005
- 2005-03-18 US US11/083,401 patent/US7309700B2/en not_active Expired - Lifetime
- 2005-03-23 WO PCT/US2005/009655 patent/WO2005097796A2/en not_active Ceased
- 2005-03-23 CN CNA2005800104438A patent/CN1938306A/zh active Pending
- 2005-03-23 EA EA200601816A patent/EA200601816A1/ru unknown
- 2005-03-23 EP EP05729416A patent/EP1740586A2/en not_active Withdrawn
- 2005-03-23 JP JP2007506248A patent/JP2007530681A/ja active Pending
- 2005-03-23 BR BRPI0509586-7A patent/BRPI0509586A/pt not_active Application Discontinuation
- 2005-03-23 MX MXPA06011324A patent/MXPA06011324A/es unknown
- 2005-03-23 AU AU2005230922A patent/AU2005230922A1/en not_active Abandoned
- 2005-03-23 CA CA002558817A patent/CA2558817A1/en not_active Abandoned
- 2005-03-23 KR KR1020067023046A patent/KR20070014164A/ko not_active Withdrawn
- 2005-03-30 UY UY28827A patent/UY28827A1/es not_active Application Discontinuation
- 2005-03-31 PE PE2005000373A patent/PE20060164A1/es not_active Application Discontinuation
- 2005-04-01 AR ARP050101292A patent/AR048360A1/es unknown
- 2005-04-01 TW TW094110415A patent/TW200602340A/zh unknown
-
2006
- 2006-07-18 ZA ZA200605930A patent/ZA200605930B/xx unknown
- 2006-09-28 IL IL178352A patent/IL178352A0/en unknown
- 2006-09-29 NO NO20064422A patent/NO20064422L/no not_active Application Discontinuation
- 2006-10-02 EC EC2006006904A patent/ECSP066904A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20060164A1 (es) | 2006-04-03 |
| AU2005230922A1 (en) | 2005-10-20 |
| MXPA06011324A (es) | 2007-03-21 |
| TW200602340A (en) | 2006-01-16 |
| ZA200605930B (en) | 2007-12-27 |
| WO2005097796A2 (en) | 2005-10-20 |
| KR20070014164A (ko) | 2007-01-31 |
| EA200601816A1 (ru) | 2007-04-27 |
| IL178352A0 (en) | 2007-02-11 |
| BRPI0509586A (pt) | 2007-10-09 |
| WO2005097796A3 (en) | 2006-01-05 |
| JP2007530681A (ja) | 2007-11-01 |
| EP1740586A2 (en) | 2007-01-10 |
| ECSP066904A (es) | 2006-12-20 |
| US20050222134A1 (en) | 2005-10-06 |
| CN1938306A (zh) | 2007-03-28 |
| CA2558817A1 (en) | 2005-10-20 |
| UY28827A1 (es) | 2005-10-31 |
| US7309700B2 (en) | 2007-12-18 |
| NO20064422L (no) | 2006-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128483A2 (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos | |
| AR077415A2 (es) | Derivados de oxindol sustituido , medicamentos que los comprenden y uso de los mismos | |
| PE20090696A1 (es) | Formas cristalinas de saxagliptina y procesos para preparar las mismas | |
| CR20190168A (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| DK291890A (da) | Pyrimidinnucleosider, fremgangsmaade til fremstilling deraf og pyrimidinderivater til anvendelse som mellemprodukter ved fremgangsmaaden samt farmaceutiske praeparater indeholdende pyrimidinnucleosiderne og anvendelse af disse til fremstilling af laegemidler til behandling af aids og infektioner af retrovirus | |
| WO2008142055A3 (en) | Antiviral agents | |
| PE20081157A1 (es) | Forma cristalina de hemifumarato de alisquireno | |
| CO5271720A1 (es) | Proceso para fabricar selectivamente hemipentahidrato y monopentahidrato de acido 3-piridil-12hidroxi-etiliden-1, 1-bisfofosnico sodio y composicion farmacetica que las contiene | |
| ES2072874T3 (es) | Cristalizacion de agua a contracorriente de etapas multiples para compuestos aromaticos. | |
| PE20030588A1 (es) | Metodos para granulacion humeda de azitromicina | |
| CO2019004190A2 (es) | Formulaciones liposomales para uso en el tratamiento del cáncer | |
| AR029412A1 (es) | Forma cristalina | |
| TW201612156A (en) | Thiol compound, method for producing thiol compound, polymer, composition, curable composition, coloring composition, cured film, and color filter | |
| AR072397A1 (es) | Proceso para la preparacion de derivados de benzoimidazol-2-ilpirimidina | |
| ES2543804T3 (es) | Polimorfo B de Ibandronato | |
| PE20090045A1 (es) | Docetaxel cristalino anhidro estable y metodo para la preparacion del mismo | |
| AR048360A1 (es) | Formas cristalinas de 5,11-dihidro-11-etil-5-metil-8-(2-((1-oxido-4-quinolinil)oxi)etil)-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-ona y un metodo para su fabricacion. | |
| UY27959A1 (es) | Nuevos agonistas ppar alfa y ppar gama | |
| UY28896A1 (es) | Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros | |
| JPS5312255A (en) | Electronic clock | |
| IL164593A (en) | Using a virus to make a pharmacist's drug to excite cancer cells for screening | |
| AR035553A1 (es) | Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos. | |
| PE20070548A1 (es) | Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico | |
| BR0315553A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, método de tratamento ou profilaxia de hiperparatireoidismo secundário, e, uso de um composto, opcionalmente em conjunto com outro composto terapeuticamente ativo | |
| PE13295A1 (es) | PROCEDIMIENTO PARA PREPARAR ß-LACTAMA CRISTALINA MONOHIDRATO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |